Iranian Blood transfusion organization has implemented a mandatory haemovigilance system to monitor Adverse Transfusion Events (ATEs) since 2009.
The scope of Iranian Haemovigilance System (IHS) encompasses all blood components issued by blood transfusion centers, all adverse reactions and all hospitals (public and private hospitals).
After preparing the standard forms, slides, different guidelines and SOPs, all health care staff including nurses and doctors as well as the staff of hospital blood banks have been trained to identify and manage all adverse reactions of blood transfusion. From January 2009 to 2016, this system was established in 612 (73%) hospitals (from 863 hospitals across the country). Hospitals use uniform forms for blood requests; monitor patients during blood administration and report all adverse reactions.
We aimed to gather and analyze transfusion reactions to help prevent their occurrence and/or reoccurrence.
- IBTO in collaboration with WHO-EMRO to prepare 15-year regional status report for blood safety and availability in EMR
- The Governing Council Meeting of Asian Association of Transfusion Medicine in Tehran
- International workshop on Strengthening Leadership and Governance of National Blood Services
- The 4th Iran International Congress of Transfusion Medicine hosts 18 countries
- The first blood bag manufacturing company opens in Iran
- IBTO Managing Director presents Iran's experience in thalassemia prevention at 35th International Congress of the ISBT
- Message from Dr. Ahmed Al-Mandhari Regional Director of EMRO on the occasion of World Blood Donor Day
- Rwanda National Blood Service: A role model for least developed countries
- Visit of Pharmaceutical & Medical equipment delegation from Oman to IBTO
- AB negative: The rarest blood type in Iran